Feb. 18, 2013
/PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
MarketVIEW: Japanese encephalitis vaccines
Japanese encephalitis (JE) is an enzootic mosquito-borne viral disease where humans are incidental "dead end" hosts. JE currently affects countries of
and Western Pacific where around 3 billion people are considered at risk. The disease mainly affects children (< 15yrs) in poor rural areas where it can result in 25% mortality (est 10,000 deaths/yr) or residual neuropsychiatric sequelae (30% of cases). There are no specific treatments for JE.
This MarketVIEW product is comprised of a comprehensive MS Excel-based model(s) + Summary executive presentation which forecast the potential commercial value of Japanese Encephalitis vaccine(s) across endemic and markets to 2030. The model(s) contain value ($ m) and volume (mio doses) predictions for endemic countries in all age segments in both the public and private sector down to vaccine type. LO, BASE & HI forecast scenarios model expected demand from newly adopting countries as postulated by the PATH JE project.
THIS PRODUCT IS A SUMMARY PRESENTATION + ONE MODEL
Contents – Summary presentation (MS PowerPoint based)ContentsAuthors noteExecutive summaryCommercial model: key outputsJE vaccine: available market (endemic/public) ($ 000s) – all children to 2030JE vaccine: available market (endemic/public) ($ 000s) – infants to 2030JE vaccine: available market (endemic/public) ($ 000s) – 1 to 15 yrs to 2030JE vaccine: endemic segment volume analysis (mio doses/yr)JE vaccine: available market (endemic/private) ($ 000s) – 1 to 15 yrs to 2030JE vaccine: market by vaccine type 2015JE vaccines: all market segments, revenues/yr (2015)JE: disease backgroundJE: transmission cycleJE: geographic distributionJE: epidemiologyJE: genotype distributionJE: country reporting/surveillanceJE: WHO reported cases 2006 - 2010JE: disease profile of main endemic countriesRisk of JE by country, region and seasonDALYs per 100,000 persons in JE endemic countriesJE: disease trends and dynamicsJE: factors contributing to increasing transmissionJE and travelersJE: control and preventionJE control: aligned with major stakeholder objectivesPATH JE project: strategic goalsJE vaccines: policy evolutionJE vaccines: immunological aspectsImpact of JE vaccinationJE vaccination and cost effectivenessCurrently licensed JE vaccines (endemic)Country status of JE control through immunizationCountry use of JE vaccine types: SEA regionCountry use of JE vaccine types: WPR regionIndia: cases and deaths 1993 – 2009India – JE priority districtsIndia – mass vaccination campaignsIndia – mass vaccination campaigns: progress to dateTransition to new JE vaccinesAvailability of new JE vaccinesJE vaccination: country future planning – SEA regionJE vaccination: country future planning – WPR regionCommercial model: detailed assumptions per WHO region/countryJE vaccine demand forecast: countries modelledJE vaccines: modelling strategyCommercial model assumptions – SEA regionCommercial model assumptions – WPR regionPricing case studies for endemic vaccinesJE vaccine prices used in modelSource materialJE vaccines (PATH): estimated implementation 2006 – 2015Timeline of JE in
1971 – 2006Japan: immunization schedule 2011 (< 20 yrs)
: JEV vaccinations given 1995 – 2009 (000s)Ensebakku subcutaneous JE vaccine: History of developmentIxiaro/JESPECT – distribution structureBibliographyAbout VacZine AnalyticsDisclaimerBack pagePAGES: 81 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model (MS Excel-based) – endemic markets (public/private)Title sheetCHARTS – VAL (private)CHARTS – VAL (pub)CHARTS – VOL (pub)GRAND VALUE SUMMARYValue by vaccine typeValue Summary (pub <1 yrs)>Value Summary (pub 1-15 yrs)Value Summary (priv 0 - 15 yrs)Global price summaryVolume Summary (pub <1 yrs)>Volume Summary (pub 1-15 yrs)Volume Summary (priv 0 - 15 yrs)Volume SummariesSEA regionBangladesh (pub)
Korean DPR (pub)